COMMUNIQUÉS West-GlobeNewswire

Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026
14/04/2026
PRINCETON, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable [...]
BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting
14/04/2026
CARSON CITY, Nev., April 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases [...]
Hinge Bio Announces First Subject Dosed in Phase 1 Trial of HB2198, a Novel B cell Depleting Agent, for Treating Autoimmune Disease
14/04/2026
First-in-human clinical trial underway to evaluate safety, tolerability and pharmacodynamic activity of HB2198 in normal healthy volunteers. A separate Phase 1 trial evaluating HB2198 in patients with Systemic Lupus [...]
Er-Kim Signs Exclusive Distribution Agreement with LEO Pharma A/S to Commercialize LOQTORZI® (toripalimab) for Nasopharyngeal and Oesophageal Cancers
14/04/2026
Er-Kim announces exclusive partnership with LEO Pharma A/S to launch LOQTORZI® across Central and Eastern Europe, expanding access to innovative cancer treatment for Nasopharyngeal and Oesophageal Cancers ISTANBUL and [...]
Aclarion Receives Pinnacle Award for AI Innovation
14/04/2026
Recognition Follows 2025 HLTH Digital Health Award for Nociscan Award Winning AI Targets a Large and Costly Chronic Low Back Pain Market BROOMFIELD, Colo., April 14, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc ., (“Aclarion [...]
R1 Announces Revenue Performance Solutions Powered by Phare OS to Help Providers Navigate Growing Complexity and Margin Pressure
14/04/2026
Latest Solutions Focus on Improving AR Recovery and Denials Management CHICAGO, April 14, 2026 (GLOBE NEWSWIRE) -- R1 (“R1” or the “Company”), the leader in healthcare revenue management, today announced the launch of [...]
Clairity Announces Update to NCCN Guidelines to Include AI Mammogram-Based Risk Tool to Identify Future Breast Cancer Risk in Women Missed by Traditional Methods
14/04/2026
Major paradigm shift incorporates five-year risk assessment and identifies increased-risk women beginning at age 35 BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Clairity, Inc. announces the National Comprehensive Cancer [...]
Prenetics’ IM8 Health Partners with Vitamin Angels to Combat Global Malnutrition, Commits to Impacting 400,000 Mothers and Children in Year One
14/04/2026
Partnership Extends IM8’s Mission Beyond Premium Nutrition to Address Malnutrition Among the World’s Most Vulnerable Populations Long-Term Goal to Impact Millions of Lives Through Sustained Funding and Awareness Vitamin [...]
Rivus Pharmaceuticals Announces First Patients Dosed in AMPLIFY Phase 2 Trial for HU6 in MASH
14/04/2026
- Top-line data expected in mid-2027; Actively planning for HU6’s late-stage development in MASH - - HU6 is potential best-in-class oral MASH therapy designed to address unmet needs in MASH through a unique energy [...]
GeneCentric to Present Data on Fragmentomics-Based ExpressCT™ Liquid Biopsy Technology at AACR 2026
14/04/2026
DURHAM, N.C., April 14, 2026 (GLOBE NEWSWIRE) -- GeneCentric , a company making precision medicine more precise by bringing gene expression biology to liquid biopsy, today announced that it will present three posters at [...]
Carlsmed Inc. to Report First Quarter 2026 Financial Results on May 5, 2026
14/04/2026
CARLSBAD, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its first [...]
Nanox Announces Collaboration with Meir Medical Center to Deploy Nanox.ARC for Orthopedic Imaging Clinical Study
14/04/2026
Enhancing emergency triage imaging with Nanox.ARC to improve efficiency and lower radiation dose Collaboration expands clinical evidence base of Nanox.ARC to support broader adoption PETACH TIKVA, Israel, April 14, 2026 [...]
Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity
14/04/2026
On track to complete 16-week, dose-finding Phase 1b study (n=240) in summer 2026 Phase 1b data will build upon Phase 1a findings that demonstrated weight loss of nearly 3% at 14 days in individuals with obesity CRB-913 [...]
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
14/04/2026
Adds dedicated business development leadership to support Tempest’s strategic priorities Will lead China outreach and cross-border partnership efforts To support ongoing partnering discussions for Phase 3-ready [...]
Genvor Announces Strategic Memorandum of Understanding with Canlab International™ to Advance Commercial Peptide Pipeline
14/04/2026
Establishes framework targeting multi-product commercialization across high-growth health and wellness categories with scalable revenue potential Woodland, CA, April 14, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB: [...]
Real-World Evidence and Industry Momentum Builds for iMDx’s Flagship GraftAssure Assay
14/04/2026
Positive real-world head-to-head data on GraftAssure TM assay to be presented at the 39 th European Immunogenetics and Histocompatibility Conference (EFI2026), April 21–24, 2026 in Edinburgh, Scotland Three posters to [...]
Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavík, Iceland on April 28th Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy
14/04/2026
SAN DIEGO, April 14, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will [...]
AVITA Medical Announces Positive Interim Results from Cohealyx® Study Demonstrating Accelerated Time to Skin Grafting
14/04/2026
Mean time to graft reduced to 13.6 days vs. 33.2 days real-world benchmark (~20 day reduction) Median time to graft of 11 days, with grafting as early as 5 days Study ongoing with full dataset expected in 2026 [...]
Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
14/04/2026
Vancouver, Canada, April 14, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]

Pages